| Cat.No. | Name | Information |
|---|---|---|
| M21387 | Narsoplimab | Narsoplimab, a fully human immunoglobulin gamma 4 (IgG4) monoclonal antibody against MASP-2, inhibits lectin pathway activation and has anticoagulant effects. |
| M21383 | Ravulizumab | Ravulizumab (ALXN1210) is a humanized monoclonal antibody that binds with high affinity to complement protein C5 and inhibits terminal complement activation, Ravulizumab can be used for the researchs of COVID-19-associated severe pneumonia, acute lung injury and acute respiratory distress syndrome. |
| M11172 | Reslizumab | Reslizumab (Sch 55700) is a humanized monoclonal antibody targeting human interleukin 5 (IL-5) for the study of eosinophilic asthma. Reslizumab effectively blocks il-5 function. Reslizumab inhibited IL-5-dependent cell proliferation with an IC50 of about 91.1 pM. |
| M10890 | Spartalizumab | Spartalizumab (anti-PD-1) is a human-derived IgG4 antibody against PD-1 that inhibits the binding of PD-L1 and PD-L2 to PD-1. PDR001 binds to PD-1 with high affinity to inhibit its biological activity; MW: 145.8 KD. |
| M10603 | Anti-human CD28 mAb | CD28 molecule exists on the surface of most T cells and is considered to be a specific surface molecule of T cells. The responsiveness of T cells to antigens is mainly mediated by the CD3/TCR complex, but it also depends on the cooperation of other molecules on the surface of T cells. |
| M10111 | Anti-human CD3 mAb | CD3 is an important marker of T cells, it is composed of five polypeptide chains: γ, δ, ε, ζ, and η. |
| M9416 | Durvalumab | Durvalumab (MEDI 4736) is an humanized anti-PD-L1 monoclonal antibody, it completely blocks the binding of PD-L1 to both PD-1 and CD80, with IC50s of 0.1 and 0.04 nM, respectively. Durvalumab was inactive against the mPD-L1. |
| M9236 | Ranibizumab | Ranibizumab (RG-6321) is a monoclonal antibody that inhibits angiogenesis by inhibiting Vascular endothelial growth factor A. Ranibizumab binds and inhibits vascular endothelial growth factor-a (VEGF-a) to inhibit neoangiogenesis. |
| M8984 | Denosumab | Denosumab is designed to target RANKL (RANK ligand), a protein that acts as the primary signal to promote bone removal/resorption. |
| M8941 | Fenebrutinib | GDC-0853 (Fenebrutinib) is a potent, selective and non-covalent bruton tyrosine kinase (Btk) inhibitor with a Ki value of 0.91 nM against BRK. |
| M6222 | Adalimumab | Adalimumab is the first fully human, recombinant IgG1 monoclonal antibody that specifically targets human TNF-alpha, MW: 144.19 KD. |
| M6103 | Cetuximab | Cetuximab is a chimeric IgG1 monoclonal antibody to EGFR that inhibits the interaction of EGFR with its ligand. For use in cellular assays, human IgG antibody can be used as an isotype control. (For human and non-humanized mice). |
| M6102 | Pembrolizumab | Pembrolizumab (pembrolizumab) is a humanized anti-PD-1 monoclonal antibody that blocks the interaction between PD-1 and its ligands PD-L1 and PD-L2. It has immune checkpoint inhibitory activity and antitumor activity. MW: 146.286 KD.(Pembrolizumab does not recognize murine PD-1 protein, humanized mice or mice expressing human PD-1 gene are required). |
| M3849 | Aflibercept | Aflibercept is a vascular epidermal growth factor (VEGF-A and PlGF) receptor inhibitor that inhibits the growth of neovascularization. It can be used to study a variety of diseases caused by ocular neovascularization. |
| M3814 | Sarilumab | Sarilumab is a human recombinant IgG1 antibody that binds to both forms of interleukin 6 receptors (IL-6R), thus inhibiting the IL-6-mediated signaling. |
| M1629 | Ramucirumab | Ramucirumab is a direct VEGFR2 antagonist, that binds with high affinity to the extracellular domain of VEGFR2 and block the binding of natural VEGFR ligands (VEGF-A, VEGF-C and VEGF-D). |
| M1622 | Secukinumab | Secukinumab (AIN457) is a high-affinity monoclonal antibody against interleukin (IL-17A). Secukinumab (AIN457) is the first-in-class anti-IL-17 agent to be used in studies of plaque psoriasis, ankylosing spondylitis, and psoriatic arthritis. |
| M1621 | Ustekinumab | Ustekinumab is a human monoclonal antibody that targets IL12 and IL23, natural proteins that regulate the immune system and immune-mediated inflammatory diseases. |
| M1618 | Vedolizumab | Vedolizumab is a humanized monoclonal antibody that specifically antagonizes Integrin (α4β7) and inhibits the binding of α4β7 to the intestinal mucosal cell adhesion molecule MADCAM-1. Vedolizumab is indicated for humanized mice. |
| M1616 | Daratumumab | Daratumumab (Daratumumab) is a first-in-class, specific anti-CD38 monoclonal antibody (IgG1). (for human or immunodeficient mice). |
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
